ARCH Venture Partners announced the closing of ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the founding and growth of early-stage biotechnology companies.
ARCH invests in early-stage companies that prevent, detect and cure disease. And Fund XIII investments to date include ArsenalBio, Metsera, Mirador Therapeutics and Xaira Therapeutics.
Fund XIII follows the $2.975 billion Fund XII announced in June 2022. And ARCH’s Managing Directors include:
— Robert Nelsen
— Keith Crandell
— Kristina Burow
— Mark McDonnell
— Steve Gillis
— Paul Berns
KEY QUOTES:
“After more than 38 years, the ARCH investment philosophy has been consistent: we bet on great science and great teams to build breakthrough companies. We believe AI and new data-driven insights into biology will help to enable a more preventive, curative and equitable healthcare system. ARCH intends to continue driving the healthcare revolution.”
-ARCH co-founder and Managing Director Robert Nelsen
“ARCH is first and foremost a company builder; we foster innovation at scale to develop new technologies and medicines as rapidly as possible. We are well-positioned to continue catalyzing the next revolutions in healthcare to benefit those who matter most: patients.”
-ARCH Managing Director Kristina Burow
“ARCH has a long history of identifying the top forward-looking trends in life sciences R&D and the individuals driving truly breakthrough scientific hypotheses. We remain incredibly excited by the pace of innovation and efforts to understand disease at a deeper level.”
-ARCH co-founder and Managing Director Keith Crandell
